# Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

> **NCT05361486** · — · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 187 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **DRUG:** Tafenoquine (TQ)

## Key facts

- **NCT ID:** NCT05361486
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361486, "Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05361486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*